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Abstract
EQ-5D is used in cost-effectiveness studies underlying many important health policy deci-
sions. It comprises a survey instrument generating a description of health states across five
domains, and a system of utility values for each state. The original 3-level version of EQ-5D
is being replaced with a more sensitive 5-level version but there little is known about the
consequences of this change. We develop a multi-equation ordinal response model incorpo-
rating a copula specification with normal mixture marginals to analyse the joint responses to
EQ-5D-3L and EQ-5D-5L in a survey of people affected by rheumatoid disease, and use it to
generate mappings between the 3-level and 5-level descriptive systems. We find significant
conflicts between the two, which would imply the reversal of an important conclusion in a
real-world evaluation of drug therapies.
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1 Introduction: EQ-5D-3L and EQ-5D-5L
The quality-adjusted life year (QALY) is one of the most widely used health benefit mea-
sures in economic evaluations of interventions, services or programmes designed to improve
health. The QALY allows health care decision makers to use a consistent approach across a
broad range of disease areas, treatments, and patients. It reflects concerns for both quality
and length of life and, in England, is the preferred outcome measure for the National Insti-
tute for Health and Care Excellence (NICE) in its appraisals of health interventions NICE
(2014). Preference-based measures such as the EQ-5D underpin the calculation of QALYs
by providing a simple descriptive profile and a single index value for health states.
EQ-5D measures patient health across five dimensions: mobility, self-care, usual activ-
ities, pain/discomfort, and anxiety/depression. The original version of EQ-5D, which has
been used in a large number of cost-effectiveness evaluations, measures each domain on a
scale with three severity levels (no problems, some or moderate problems, extreme problems).
Up to 35 = 243 states of health can be described in this way, and each has been assigned a
uility score on the basis of an analysis (Dolan, 1997) of preferences over length and quality
of life using data from the general public. Full health is assigned a utility score of 1 and 0 is
equivalent to death, with negative values indicating health states worse than death.
Concerns about (lack of) sensitivity and floor/ceiling effects in the standard version re-
cently led to the development of a new version, the EQ-5D-5L. The descriptive system
covers the same original five dimensions but the number of levels within each dimension has
been extended from three to five (no problems, slight problems, moderate problems, severe
problems, extreme problems). In addition, some of the wording has been modified to aid
consistency and understanding.1 The maximum number of health states that can be de-
1See the EuroQol website http://www.euroqol.org/eq-5d-products/how-to-obtain-eq-5d.html for
examples of the question wording used in EQ-5D-3L and EQ-5D-5L.
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scribed with the new version is 55 = 3125. Several studies have reported better measurement
properties in moving from the EQ-5D-3L to EQ-5D-5L in both specific patient and general
population samples (Pickard et al., 2007; Janssen et al., 2008a,b, 2013; Scalone et al., 2013;
Agborsangaya et al., 2014; Jia et al., 2014; Pattanaphesaj and Thavorncharoensap, 2015).
Utility value sets for EQ5D-5L have been released for England (Devlin et al., 2016), Japan
(Ikeda et al., 2015), Canada (Xie et al., 2016) and Uruguay (Augustovski et al., 2015) and
similar work is underway in many other countries.
Many studies now include EQ-5D-5L instead of the standard version. Since these studies
will form part of the evidence in future economic evaluations, it is important to assess the
likely consequences for economic evaluation decisions of moving across the two different
versions of EQ-5D, and to develop a basis for using the very large stock of existing evidence
based on the 3-level version. In this paper we specify a joint model of the responses to EQ-
5D-3L and EQ-5D-5L which allows us to map coherently from EQ-5D-3L to EQ-5D-5L and
the reverse. We apply the model to investigate the consistency of the responses to the two
descriptive systems, the implied differences in the utility values and the impact on economic
evaluation decisions of moving between the two versions in a representative decision problem.
We begin in section 2 by describing the North American dataset we use for the EQ-5D-3L
and EQ-5D-5L comparison – one of the few datasets available in which both variants of the
instrument are observed in the same survey instrument. In sections 3 and 4, we develop a new
flexible modelling approach for analysing the 3-level and 5-level data and report the results
of its application. Section 5 uses the results to carry out mapping from 3-level to 5-level and
vice versa, and section 6 shows the impact of the switch from 3-level to 5-level EQ-5D on
the outcome of a representative evaluation of four competing drug therapies for rheumatoid
arthritis. Our evidence suggests that a decision by policy-makers to move from EQ-5D-3L
to EQ-5D-5L will raise significant doubts about the reliability of many past decisions.
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2 The NDBRD dataset
The National Data Bank for Rheumatic Diseases (NDBRD) is a register of patients with
rheumatoid disease, primarily recruited by referral from US and Canadian rheumatologists.
Information supplied by participants is validated by direct reference to records held by
hospitals and physicians.2 Full details of the recruitment process are given by Wolfe and
Michaud (2011). The EQ-5D responses and other patient-supplied data are collected by
various means, primarily postal and web-based questionnaires completed directly by patients.
Data collection began in 1998 and continues to the present, in waves administered in January
and July of each year. In 2011, there was a switch from 3-level to the 5-level version of EQ-
5D and both versions were collected in parallel during the January 2011 wave, to allow
the effects of the switch to be accommodated in analyses spanning the whole period. Our
principal aim is to use data from that wave of the survey to estimate a joint model of the 3-
and 5-level responses, which can then be used to map from 3- to 5-level EQ-5D during the
pre-2011 period and from 5- to 3-level EQ-5D after January 2011. It then becomes possible
to investigate the consistency of the two versions of EQ-5D and assess the impact of mapping
between them.
2.1 EQ-5D response distributions
Figure 1 shows histograms of the NDBRD sample response distributions for the 3- and 5-
level versions of each domain of EQ-5D. There are clear differences between the distributional
shapes for different domains: self-care and anxiety/depression have a dominant mode at the
first category; the mobility and usual activities domains also have a decreasing profile but
with a heavier central section, while the pain/discomfort domain shows a strong mode in
the centre of the distribution. This variation in the shape of the component distributions
2A minority of cases come by self-referral, with medical details obtained by NDB in the same way.
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underlines the need to use a suitably flexible model specification to analyse the relationship
between variants of EQ-5D.
Figure 1: Response histograms for EQ-5D-3L and EQ-5D-5L
(Jan 2011 wave of NDBRD, n = 5192)
2.2 Utility scores
For each possible combination of EQ-5D responses, there is a utility value which allows
overall health-related quality of life to be estimated and compared across individuals and
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conditions. We use the value sets produced by Dolan (1997) and Devlin et al. (2016) for
the 3- and 5-level versions of the instrument which, at present, are the standard choices for
QALY measurement in England. Dolan (1997) used data from a representative sample of the
UK population (2,977 respondents). Each respondent valued 13 hypothetical health states
using the time trade-off (TTO) method, generating valuations for a subsample of 42 of the
243 health states described by the EQ-5D-3L. The data were then modelled using regression
methods to impute utility values for the remaining health states. Devlin et al. (2016) used
a sample of the English population (996 respondents) who valued 10 health states using
a composite TTO approach, and 7 paired comparisons of health states via discrete choice
experiment tasks. The model selected for the EQ-5D-5L value set for England was a hybrid
model using both sets of data (Feng et al., 2016).
Figure 2 shows kernel density estimates of the distributions of utility scores in the NDBRD
data, aggregated across all five domains. The distribution is smoother for the 5-level version,
particularly towards the top of the range, and this finer structure is a major reason for its
adoption in practice. The distribution of utility scores for the 3-level version of EQ-5D has
two particularly worrying features. There are ranges with probability mass at or close to
zero, particularly around 0.8-1.0 and 0.3-0.45. Consequently, methods for mapping to and
from EQ-5D-3L which implicitly assume a smooth positive density can give very poor results
(Herna´ndez-Alava et al., 2012). The second striking feature of the distribution for EQ-5D-
3L is the large group of cases with utility values close to zero, implying a non-negligible
proportion of patients with rheumatoid arthritis (RA) who are in a state comparable to,
or worse than, death. The outcomes of evaluation studies often rest on the ability of a
therapy to improve the quality of life (QoL) of patients in very poor health states, so the
(perhaps implausibly) large frequency of such cases is a potential source of bias in NICE
recommendations.
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Figure 2: Smoothed empirical distribution functions of EQ-5D-3L and EQ-5D-5L
(Jan 2011 wave of NDBRD, n = 5192)
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Table 1 summarises the January 2011 NDBRD data on the value scores for the two
variants of EQ-5D in terms of their correlation with each other, with basic demographic
characteristics, and with a set of clinical outcome measures. They show a high correlation
between the two variants of EQ-5D, but the 5-level version has greater sensitivity, since
correlations with demographics and clinical outcomes (in the lower panels of Table 1) are
uniformly higher for EQ-5D-5L.
Table 2 shows that there is a systematic difference in the 3-level and 5-level utility scores,
with the old system generating utilities averaging (in the NDBRD data) only 88% of the
utility values given by the new system. This alone could make a significant difference to some
evaluation results. It would be inadvisible to address the issue with a simple proportional
adjustment, since the ratio of mean scores is not constant but decreases as both general
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Table 1: Spearman correlations of 3- and 5-level EQ-5D
(Jan 2011 wave of NDBRD, n = 4856)
Variable EQ-5D-3L EQ-5D-5L
EQ-5D-3L 1.000 0.849
EQ-5D-5L 0.849 1.000
Female -0.054 -0.072
Age 0.030 0.055
HAQ score (0-3) -0.735 -0.766
Pain scale (0-10) -0.707 -0.711
Overall RADAI score -0.737 -0.753
Global severity (0-10) -0.698 -0.726
Disease duration (months) -0.053 -0.067
Polysymptomatic distress scale 0.462 0.487
Fatigue scale (0-10) -0.633 -0.670
Sleep disturbance scale (0-10) -0.506 -0.540
Arthritis activity (general) -0.611 -0.630
Arthritis activity (today) -0.672 -0.678
RADAI joints (score) -0.641 -0.653
RADAI joints (count) -0.581 -0.593
Morning stiffness (0-6) -0.538 -0.559
Co-morbidity index (0-9) -0.344 -0.362
Physical component score (SF-6D) 0.727 0.767
Mental component score (SF-6D) 0.475 0.523
Health satisfaction (0-4) -0.638 -0.671
severity and pain increase, so the differences are minor at the top end of EQ-5D and much
larger at the bottom. Table 2 gives means classified by levels of general disability (in three
groups, scores 0-1, 1-2 and 2-3) and pain (in five groups 0-2, 2-4, 4-6, 6-8 and 8-10), as
classified by the Stanford Health Assessment Questionnaire (HAQ). The HAQ is widely
used by clinicians to measure treatment outcomes; see Bruce and Fries (2003) for a review.
3 A copula model with mixture marginals
Define Y3id ∈ {0,1,2} and Y5id ∈ {0,1,2,3,4} to be the reported outcomes for the dth domain
(d = 1 . . .5) of the 3- and 5-level forms of EQ-5D. The model is a system of ten latent
regressions, arranged in the five domain groups, with domain d containing the equations for
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Table 2: Means of EQ-5D-3L and EQ-5D-5L utility scores by severity of condition
(Jan 2011 wave of NDBRD, n = 5192)
3L 5L Ratio
Overall 0.68 0.77 0.88
By general severity (HAQ) and pain scale category
General1 Pain2 3L 5L Ratio
1 1 0.87 0.92 0.95
1 2 0.76 0.86 0.89
1 3 0.72 0.82 0.88
1 4 0.67 0.78 0.87
1 5 0.51 0.72 0.71
2 1 0.74 0.81 0.91
2 2 0.66 0.75 0.88
2 3 0.60 0.72 0.83
2 4 0.52 0.64 0.81
2 5 0.30 0.53 0.56
3 1 0.63 0.70 0.90
3 2 0.54 0.64 0.84
3 3 0.45 0.56 0.81
3 4 0.35 0.48 0.73
3 5 0.15 0.36 0.42
1 Groups corresponding to HAQ scores (1) [0-1); (2) [1-2) and (3) [2-3]
2 Groups corresponding to pain scores (1) [0-2); (2) [2-4); (3) [4-6); (4) [6-8) and (5) [8-10]
Y3id and Y5id:
Y ∗3id = Xidβ3d +U3id
Y ∗5id = Xidβ5d +U5id
⎫⎪⎪⎬⎪⎪⎭ d = 1...5 (1)
where i indexes individual cases and we assume random sampling so that all sampled vari-
ables are independent across individuals. Xi1...Xi5 is a collection of row vectors of covariates
and β3d, β5d are column vectors of cefficients conformable with Xid. We assume that the
covariate vector Xid is the same for both the 3-level and 5-level version of the rth domain,
but may differ between domains. U3id, U5id are unobserved residuals which may be stochasti-
cally dependent and non-normal. The latent dependent variables Y ∗3id, Y ∗5id are not observed
directly but they have observable ordinal counterparts, Y3id, Y5id, generated by the following
threshold-crossing conditions:
Ykid = q iff Γkqd ≤ Y ∗kid < Γk(q+1)d ; q = 1...Qk ; k = 3,5 (2)
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where Qk = 3 or 5 is the number of categories of Ykid and the Γkqd are threshold parameters,
with Γk1d = −∞ and Γk(Qk+1)d = +∞.
We decompose the residual Ukid into a single between-group factor which represents the
individual’s general tendency to give more or less positive responses and a specific residual
correlated within but not between domains:
Ukid = ψkdVi + εkid (3)
where the ψkd are a set of ten parameters. Supressing the i subscript, we make the following
standard assumptions:
V upmodels εkd∣X , k = 3,5, d = 1 . . .5 (4)
εkd upmodels εlg ∣X , k = 3,5, d ≠ g (5)
ε3d upmodels_uni0338 ε5d∣X , d = 1 . . .5 (6)
where X = [X1 . . .X5] and upmodels and upmodels_uni0338 denote statistical independence and (possible) depen-
dence respectively.
3.1 Within-domain variation
We use a 1-parameter copula representation to capture the dependence between the 3-level
and 5-level responses for any domain. When applying this approach in a single domain, we
assume that Vi = 0 almost surely.3. Define Fd(ε3d, ε5d) to be the distribution function (df)
for domain d and F3d(ε3d) = Fd(ε3d,∞) and F5d(ε5d) = Fd(∞, ε5d) to be the marginals. The
joint residual df for domain d is specified as:
Fd(ε3d, ε5d) = cd (G3d(ε3d),G5d(ε5d); θd) (7)
3This is essentially equivalent to using the copula representation for the whole residuals U3d, U5d rather
than ε3d, ε5d
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where Gkd(.) is the marginal df of εkd and θd is a parameter controlling the pattern of
dependence between ε3d and ε5d. The copula function cd ∶ [0,1] × [0,1] → [0,1] has the
properties cd(0, u) = cd(u,0) = 0 and cd(1, u) = cd(u,1) = u for any u ∈ [0,1] (Trivedi and
Zimmer, 2005). We consider the following candidate forms:
Gaussian: c(ε3, ε5) = Φ (Φ−1(ε3),Φ−1(ε5); θ)
where Φ(., .; θ) is the distribution function of the bivariate normal with correlation coefficient
−1 ≤ θ ≤ 1 and Φ−1(.) is the inverse of the univariate N(0,1) df
Clayton:
c(ε3, ε5) = ⎧⎪⎪⎨⎪⎪⎩ [max{ε
−θ
3 + ε−θ5 − 1,0}]−1/θ for 0 < θ ≤∞
ε3ε5 for θ = 0
Frank :
c(ε3, ε5) = ⎧⎪⎪⎨⎪⎪⎩ −
1
θ ln(1 + (e−θε3−1)(e−θε5−1)e−θ−1 ) for θ ≠ 0
ε3 ε5 for θ = 0
Gumbel : c(ε3, ε5) = exp (− [(− ln ε3)θ + (− ln ε5)θ]1/θ) for θ ≥ 1
Joe: c(ε3, ε5) = 1 − [(1 − ε3)θ + (1 − ε5)θ − (1 − ε3)θ(1 − ε5)θ]1/θ for θ ≥ 1
These are capable of representing a range of dependence structures. The Gaussian and
Frank copulas are similar in the sense that both allow for positive and negative dependence
and dependence is symmetric in both tails. However, compared to the Gaussian copula,
the Frank copula generates dependence weaker in the tails and stronger in the centre of
the distribution. The Clayton, Gumbel and Joe copulas allow only positive dependence,
and dependence in the tails is asymmetric. The Clayton copula exhibits strong left tail
dependence and relatively weak right tail dependence. Thus, if two variables are strongly
correlated at low values but not so correlated at high values, then the Clayton copula is a
good choice. The Gumbel and Joe copulas display the opposite pattern with weak left tail
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dependence and strong right tail dependence. Right tail dependence is stronger for the Joe
than the Gumbel copula.
The within-domain specification is completed by a normal mixture assumption which
allows the residuals to have a non-normal form:
G(ε) = piΦ ((ε − µ1)/σ1) + [1 − pi]Φ ((ε − µ2)/σ2) (8)
where: 0 ≤ pi ≤ 1 is the mixing parameter; (µ1, µ2) and (σ1, σ2 ≥ 0) are location and dispersion
parameters constrained to satisfy the mean and variance normalizations piµ1 + (1 − pi)µ2 ≡ 0
and pi (σ21 + µ21) + (1 − pi) (σ22 + µ22) = 1. These normal mixtures are able to capture a wide
range of distributional shapes, especially skewness and bimodality. The mixture form (8) can
be implemented with various degrees of generality, by assuming the same parameter values
(pi,µ1, µ2, σ1, σ2) for all residuals, or allowing them to vary with domain d = 1...5 and/or
EQ-5D level k = 3,5.
Conditional on Xd, the probability of observing any values Y3d = yq and Y5d = r is:
P (q, r∣Xd) = cd (Gkd(q + 1),Gkd(r + 1)) − cd (Gkd(q + 1),Gkd(r))
−cd (Gkd(q),Gkd(r + 1)) + cd (Gkd(q),Gkd(r)) (9)
where Gkd is shorthand for Gkd (Γkqd −Xdβkd). Thus, calculating the likelihood for a domain-
specific bivariate model requires four copula evaluations for each sample observation.
3.2 Between-domain variation
In high-dimensional ordinal-variable applications, copula models can become infeasible. In
our application with 10 paired domain indicators, the joint likelihood is the probability of a
10-dimensional hyper-rectangle [a0,1, a1,1)×. . .×[a0,10, a1,10). Conditional on X =X1 . . .X5, V ,
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this probability can in principle be constructed from a 10-dimensional copula C(.):
P (Y31, Y51, . . . , Y35, Y55∣X,V ) = 1∑
j1=0 . . .
1∑
j10=0(−1)j1+...+j10C (G31(aj1,1), . . . ,G55(aj10,10)) (10)
This could require 210 = 1024 evaluations of the copula, which is both time-consuming and
vulnerable to build-up of truncation error in finite arithmetic. Possible solutions to the
problem work by imposing structure on the copula, building it up from bivariate sub-copulas.
The most convenient of these methods are based on vine structures Bedford and Cooke
(2002), particularly the specific D-vine form (Panagiotelis et al., 2012).
However, the D-vine structure is most convincing when there is a natural ordering of the
observed variables, particularly temporal sequencing (as in the application by Panagiotelis
et al. (2012) to a sequence of four observations on headache spaced through the day). In
our case, although the component items of EQ-5D-5L were asked in sequence and then the
items of EQ-5D-3L later in the questionnaire, this ordering of items does not correspond
at all to the natural connections between the 3-level and 5-level items through their shared
inherent meaning. For that reason, we adopt a different approach, using five separate bi-
variate copulas for the five domains of EQ-5D, and connecting those domains via the latent
factor V which represents the respondent’s background response behaviour. In the most gen-
eral specification, we allow V to have a two-part normal mixture distribution with density
p
s1
φ ([V −m1]/s1)+ 1−ps2 φ ([V −m2]/s2) where 0 ≤ p ≤ 1, s1, s2 ≥ 0 and m1,m2 are parameters.
The joint distribution of (Y31, Y51) . . . (Y35, Y55) is:
Pr (Y31, Y51 . . . Y35, Y55∣X) = ∫ 5∏
d=1P (Y3d, Y5d∣Xd, v) [ ps1φ(v −m1s1 ) + 1 − ps2 φ(v −m2s2 )]dv
(11)
We use Gauss-Hermite quadrature to evaluate the integral in (11) at each observation to
give the likelihood function.
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4 Modelling results
Our aim is to estimate the joint distribution of the responses to the 3L and 5L variants of
the EQ-5D survey instrument, conditional on demographic characteristics (age and gender),
and clinical measures of the severity of the underlying rheumatic condition. We use seven
covariates: age, gender, the HAQ disability score, the pain scale, and the squares and product
of the HAQ and pain scales.
The HAQ is based on patient self-reporting of the degree of difficulty experienced over the
previous week in eight categories: dressing and grooming, arising, eating, walking, hygiene,
reach, grip, and common daily activities. It is widely used by clinicians to measure health
outcomes. It is scored in increments of 0.125 between 0 and 3 (although it is standard to
consider it fully continuous), with higher scores representing greater degrees of functional
disability. The HAQ instrument also includes separately a patient self-report of pain scored
on a Visual Analogue Scale (0-10).
4.1 Domain-specific modelling
We first examine each of the five domains of EQ-5D separately using a bivariate approach,
implemented in the Herna´ndez-Alava and Pudney (2016) Stata bicop routine. Table 3
summarises the sample fit of alternative copula functions for the 3- and 5-level variants for
each of the five domains, where we retain the standard assumption of Gaussian marginals.
There is no single best choice of copula: the Gaussian form fits best for dimensions 1 and 3
(mobility and usual activities), the Frank copula fits best for dimensions 2 and 5 (self-care and
anxiety/depression) while the Gumbel copula fits best for the pain/discomfort dimension.
This coincides with differences in the empirical distributions of Figure 1 between these three
groups of domains. The Frank copula (which allows weaker dependence in the tails than
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the centre of the distribution) works better than the Gaussian copula when the tails of
the response distribution are relatively heavy. The Gumbel copula which has asymmetric
dependence in the tails (stronger dependence at higher values) fits better when there is a
central mode and implies different patterns of dependence in both tails of the distribution.
Table 2 also gives the results of the Wald test of the null hypothesis that the coefficient
vectors relating the (latent) response to age, gender and disease severity are identical in the
3- and 5-level variants. The hypothesis is clearly rejected for the domains of mobility and
pain. This finding shows that the effect of the move to 5 levels is not simply a uniform
re-alignment of the response level.
Table 3: Sample fit of domain-specific models for alternative copula functions with Gaussian
marginals)
Copula
Gaussian Frank Clayton Gumbel Joe
Mobility domain
Log-likelihood -6656.54 -6665.73 -6727.46 -6669.82 -6736.73
χ2(7) for H0 ∶ β3 = β5 29.02∗∗∗ 29.49∗∗∗ 23.82∗∗∗ 33.64∗∗∗ 37.14∗∗∗
Self-care domain
Log-likelihood -4221.35 -4212.35 -4248.89 § §
χ2(7) for H0 ∶ β3 = β5 8.31 5.98 5.35
Usual activities domain
Log-likelihood -6772.96 -6796.04 -6866.11 -6785.64 -6829.65
χ2(7) for H0 ∶ β3 = β5 10.87 10.22 10.89 11.23 11.53
Pain/discomfort domain
Log-likelihood -6148.63 -6148.07 -6190.84 -6147.80 -6199.63
χ2(7) for H0 ∶ β3 = β5 29.75∗∗∗ 30.26∗∗∗ 32.71∗∗∗ 29.09∗∗∗ 26.82∗∗∗
Anxiety/depression domain
Log-likelihood -6243.59 -6238.86 -6300.55 -6244.72 -6302.70
χ2(7) for H0 ∶ β3 = β5 12.05∗ 8.56 5.10 10.66 11.86
Best-fitting models in bold type (all models have 15 parameters). Statistical significance: * = 10%, ** = 5%, *** = 1%. § No convergence.
We also explored the possibility of non-normality using a 2-part Gaussian mixture for each
residual. The assumption of normal marginals was acceptable in terms of the Akaike (AIC)
and Bayesian (BIC) information criteria for the mobility, self-care and anxiety/depression
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domains, but there was significant evidence of modest departures from normality for the
usual activities and pain/discomfort domains. Table 4 summarises the preferred specifica-
tions for those two domains, comparing them with the simpler Gaussian-marginal models.
Note that the conclusions about the equality of coefficients for these two dimensions are
not affected by the non-normality of the residual distributions. Figure 3 plots the residual
distributions for these two dimensions and compares them to the N(0,1) distribution. The
residual distributions for the usual activities dimension and for the EQ-5D-5L pain/anxiety
dimension are similar, both with a fatter right tail of the distribution. The residual distribu-
tion for the EQ-5D-5L pain/anxiety dimension departs from normality with a much bigger
central mode consistent with its unique distributional shape in Figure 1.
Table 4: Non-normality in residual distributions
Gaussian marginals Non-Gaussian marginals
Preferred Coefficient
mixture equality
Domain AIC BIC specification AIC BIC test: χ2(7)
Usual activities1 13587.9 13725.5 equal 13550.5 13707.8 8.39
Pain/discomfort2 12337.6 12475.3 unequal 12252.9 12429.9 40.91∗∗∗
Statistical significance: * = 10%, ** = 5%, *** = 1%.. 1 Gaussian copula. 2 Gumbel copula.
4.2 Joint modelling of all domains
We now examine the joint model. Table 5 summarises the sample fit of alternative joint
models4. All of them are based on the best fitting copulas for each dimension found in the
last section (the Gaussian copula for mobility and usual activities, Frank for self-care and
anxiety/depression and Gumbel for pain/discomfort). Model (a) is the baseline model with
no mixtures in ε; model (b) allows a common mixture, constrained to be the same for the
residuals in all 10 equations; and model (c) allows for one common mixture for the usual
4The likelihood functions are calculated using Gauss-Hermite quadrature with 15 integration points.
Differences in the parameter estimates are negligible when varying the number of integration points.
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Figure 3: Residual distribution for the usual activities domain
(constrained equal for 3- and 5-level residuals)
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Figure 4: Unconstrained residual distributions for the pain/discomfort domain
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(b) 5-level
activities domain and 2 unequal mixtures for the pain/discomfort domain, following the
pattern of the domain-specific results. The joint log-likelihood, AIC and BIC for the model
with independent EQ-5D dimensions are -29958.431, 60144.86 and 60892.12 respectively,
indicating that the joint model provides a better fit to the data. The joint model with
a common mixture, model (b), gives the best fit to the data according to AIC and BIC.
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The conclusions about the equality of coefficients are not affected by the choice of residual
distributions and are in line with the conclusions of the domain-specific bivariate models.
The estimated coefficients of the domain-specific bivariate and joint models can be found in
Appendix Table A1.
Table 5: Sample fit of joint copula models
Type of mixture in ε
(a) None (b) Equal (c) Unequal
Log-likelihood -29197.46 -29136.23 -29132.50
Number of parameters 115 118 124
AIC 58624.91 58508.46 58513.00
BIC 59378.73 59281.93 59325.80
Coefficient equality
Mobility domain
Equality of β χ2(7) 26.59∗∗∗ 26.53∗∗∗ 25.69∗∗∗
Equality of ψ χ2(1) 0.18 0.29 0.00
Equality of β and ψ χ2(8) 28.59∗∗∗ 26.53∗∗∗ 28.73∗∗∗
Self-care domain
Equality of β χ2(7) 4.14 3.50 3.99
Equality of ψ χ2(1) 3.02∗ 3.37∗ 4.17∗∗
Equality of β and ψ χ2(8) 9.60 8.91 10.80
Usual activities domain
Equality of β χ2(7) 8.81 7.93 9.39
Equality of ψ χ2(1) 0.33 0.21 0.45
Equality of β and ψ χ2(8) 12.77 10.82 11.88
Pain/discomfort domain
Equality of β χ2(7) 31.64∗∗∗ 30.19∗∗∗ 36.58∗∗∗
Equality of ψ χ2(1) 18.80∗∗∗ 21.42∗∗∗ 29.27∗∗∗
Equality of β and ψ χ2(8) 46.98∗∗∗ 50.65∗∗∗ 66.01∗∗∗
Anxiety/depression domain
Equality of β χ2(7) 9.27 8.70 9.36
Equality of ψ χ2(1) 2.68 2.75∗ 3.75∗
Equality of β and ψ χ2(8) 11.07 10.54 11.99
Statistical significance: * = 10%, ** = 5%, *** = 1%.
Figure 5 illustrates the effect of the differences in the distribution functions (df) of the
latent variables evaluated at the average across sample values of the covariates. For both
models the df’s of the underlying latent variables of the 3- and 5-level EQ-5D in the self-
care and anxiety/depression domains are almost identical. Moreover, the position of the
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two thresholds of the 3-level version are consistent with the idea of a re-alignment of the
response levels, where the first and the second thresholds of the 3-level version fall respectively
between the first and second, and third and fourth thresholds in the 5-level version. The
df’s in the usual activities domain are very similar in the domain-specific model; athough
slightly less so in the joint model, the differences are not statistically significant. For the
mobility and pain/discomfort domains, the differences portrayed in the graphs are sizeable
and statistically significant in both models. The pain/discomfort domain displays the most
noticeable difference between the df’s. The mobility domain is unique in that the df of the
3-level version lies to the left of the df of the 5-level version, the reverse is true for all other
domains.
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Figure 5: Domain comparisons: distribution functions of the latent variables evaluated at the
average across sample values of the covariates
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5 Mapping
The best method of mapping between alternative preference-based measures depends on the
nature of the cost-effectiveness study in which the measure is to be used. Suppose, for exam-
ple, that the study is to be done on the new 5-level basis, but the available evidence comes
from a clinical trial in which the older EQ-5D-3L scale is measured. The key concept is the
mean QALY, which should be constructed as E {Q(υ5(Y5))}, where E{.} is the expectation
with respect to whatever population is potentially affected by the treatment.
There are two technical issues to be considered in mapping from 3L evidence to 5L-based
evaluation. First, the form of the function, Q(.), which maps utilities into QALYs. In most
evaluation studies, the QALY calculation Q(.) is a linear function of the utilities, so that
E {Q(υ5(Y5))} = Q (E{υ5(Y5)}). In other words, we can simply predict the utility outcome
υ(Y5) and use that prediction in calculating QALYs. If the predictor is an unbiased (or
consistent) estimator of E [υ(Y5)], it will give an unbiased (consistent) evaluation of the
expected QALY.
The second issue is the choice of predictor for υ(Y5). We have argued here that a
predictor based on a full model of Pr(Y5∣Y3,X) uses more information and is capable of
giving better results than the alternative approach to mapping, which attempts to model
E(υ5(Y5)∣υ3(Y3),X) directly – often using methods like linear regression which are not well
suited to the non-standard distributions involved. When using our approach, it is im-
portant to realise that the utility scales υ(.) are nonlinear functions of the vector Y , so
E(υ5(Y5)) ≠ υ5(E[Y5]). We should not map the observed 3-level health description Y3 into
the 5-level descriptive system Y5 and then apply the utility scale υ5(.). Instead, the appropri-
ate method is to use the model estimated from NDBRD data to evaluate the probability of
each possible configuration of Y5 conditional on Y3,X and use those probabilities as weights
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to evaluate the conditional expectation of υ. Specifically, the conditional df of the valuation
υ5 is:
Pr (υ5(Y5) ≤ Υ∣Y3,X) = ∑
Y5∈UΥPr(Y5∣Y3,X) (12)
where UΥ is the set {Y5 ∶ υ5(Y5) ≤ Υ} and Υ is any given constant. The mean of the distri-
bution is:
E (υ5(Y5)∣Y3,X) = ∑
Y5∈S5 υ5(Y5)Pr(Y5∣Y3,X) (13)
where S5 is the set of (3125) possible values that the vector Y5 might take.
In the published literature, several authors have commented on the loss of variation
induced by mapping (Rivero-Arias et al., 2010; Brazier et al., 2010; Longworth and Rowen,
2011; Fayers and Hays, 2014). The sample variance of the mean predictor (13) will always be
lower than the variance of the unknown true υ5(Y5), because the modelling process can only
predict variation in υ5(Y5) arising from Y3 and X, not the other “unexplained” components
of variation. In standard cases where the QALY calculation is linear in utilities, this does not
matter, since only the conditional mean of υ5(Y5) is required. If the aim were to estimate
the variance of υ5(Y5), one would not do it by using the variance of the predictor (13);
instead, the appropriate method would be to calculate directly the variance of the estimated
distribution (12), which would give a consistent estimate of var(υ5(Y5)) if the mapping
model is correctly specified and estimated.
Both the distribution (12) and its mean (13) can be evaluated at the sample values
Yi3,Xi, averaged over the whole sample or a subsample, and then compared with the cor-
responding empirical df or mean of the directly observed 3-level scores, υ3(Yi3). This can
be done empirically for the pre-January 2011 waves of the NDBRD dataset and in reverse
(predicting Y3 conditional on Y5) for the post-January 2011 waves. Figure 6a uses the
set of domain-specific bivariate models (assuming independence across domains) to com-
pare the predictive df n−1∑ni=1Pr (υ5(Y5) ≤ Υ∣Yi3,Xi) and the directly-observed empirical
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df n−1∑ni=1 1 (υ3(Yi3) ≤ Υ) for the Jan 2010 wave of NDBRD, where 1(.) is the indicator
function. Figure 6b makes the reverse comparison of the predictive df for υ3(Y3) with the
empirical df of υ5(Y5) for the Jan 2012 wave. Figure 7 makes the same comparisons for the
joint model allowing for between-domain correlation.
There are three striking features of Figures 6 and 7, with important implications for
the economic evaluations carried out for public bodies like NICE. First, the predictive and
actual distributions of the 5-level variant of EQ-5D are similar and much smoother than
the corresponding distributions for the 3-level variant. This is an encouraging finding: if a
decision maker elects to recommend the use of the new 5-level instrument and associated
scoring, it may be possible to continue to use older 3-level-based evidence with appropriate
mapping to 5-level.
Second, the predictive and actual distributions for the 3L variant differ in one important
feature: the prediction of EQ-5D-3L from the 5-level responses (Figures 6b or 7b) fails
to capture the hump in the directly-observed empirical distribution in the neighbourhood
of zero. This is clearly a feature of the 3-level utility value set, rather than a mismatch
between the 3-level and 5-level descriptive systems. This finding suggests that it would
be inappropriate for decision makers to retain the older 3-level instrument and tariff for
economic evaluations, having to rely on mapping data from new trials.
Third, there is a large difference between the 3-level and 5-level distributions of EQ-5D
scores, whether directly observed or mapped. Utility scores tend to be systematically higher
under the 5-level scoring scheme, so the df for EQ-5D-3L lies entirely to the left of the df for
EQ-5D-5L. If no other adjustment were made, this alone might be enough to change many
evaluation results, in the absence of offsetting adjustments to the evaluation methodology.
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Figure 6: Cross-mapping based on independent domain-specific bivariate models
(a) Jan 2010: 3-level→5-level (b) Jan 2012: 5-level→3-level
Figure 7: Cross-mapping based on the joint model with between-domain correlation
(a) Jan 2010: 3-level→5-level (b) Jan 2012: 5-level→3-level
Table 6 shows average values of directly-measured υ3(Y3) and the prediction
E[υ5(Y5)∣Y3,X] for the 2010 wave of NDBRD, and of the prediction E[υ3(Y3)∣Y5,X] and
directly-measured υ5(Y5) for the 2012 wave using the joint model. Results are given for the
whole sample and subgroups defined in terms of disease severity and demographic character-
istics; sample standard deviations of the measured and predicted utilities are are also shown.
As expected, there are higher mean values and smaller standard deviations for the EQ-5D-
5L scores (whether predicted or directly observed) than for EQ-5D-3L, resulting from the
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different scoring of poor health states by the two value sets. Another consequence of this is
the much steeper severity gradient for the mean EQ-5D-3L utilities than for EQ-5D.
There is a slight tendency for both the 3-level and 5-level utilities to decline over time as
the health states of those individuals who appear in both waves tend to worsen. However,
the means of predicted and directly-observed versions of each measure are remakably close
both overall and in terms of their severity and demographic profiles.
We also see the anticipated smaller standard deviations of the predicted than directly-
observed utilities as a consequence of the use of expected value prediction. This is of no
importance for the evaluation described in the next section (since the criterion is based on
the mean QALY), but it would be a concern for any evaluation that aims to investigate the
distributional pattern of QALY gains within each population group. In that case, appropriate
measures constructed from the full distribution (12) would need to be used.
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Table 6: Means and standard deviations of actual and predicted (joint model)
EQ-5D-3L and EQ-5D-5L by severity of condition, age and gender.
(NDBRD. January 2010 wave n = 3877; January 2012 wave n = 3911)
January 2010 January 2012
EQ-5D-3L EQ-5D-5L EQ-5D-3L EQ-5D-5L
(actual) (predicted) (predicted) (actual)
mean (SD) mean (SD) mean (SD) mean (SD)
Overall 0.70 0.79 0.69 0.78
(0.25) (0.16) (0.21) (0.19)
Severity group
Mild 0.88 0.92 0.87 0.92
(HAQ group 1, Pain group 1) (0.12) (0.04) (0.08) (0.07)
Medium 0.62 0.70 0.61 0.72
(HAQ group 2, Pain group 3) (0.15) (0.09) (0.11) (0.11)
Severe 0.12 0.39 0.12 0.31
(HAQ group 3, Pain group 5) (0.30) (0.15) (0.19) (0.21)
Female <65 0.70 0.78 0.68 0.77
(0.26) (0.17) (0.23) (0.20)
Male <65 0.71 0.80 0.67 0.77
(0.25) (0.16) (0.24) (0.20)
Female 65-79 0.71 0.79 0.69 0.79
(0.24) (0.15) (0.20) (0.17)
Male 65-79 0.73 0.82 0.73 0.82
(0.22) (0.15) (0.19) (0.15)
Female ≥ 80 0.65 0.76 0.66 0.76
(0.25) (0.17) (0.20) (0.18)
Male ≥ 80 0.74 0.82 0.70 0.79
(0.17) (0.12) (0.17) (0.16)
6 The impact on cost-effectiveness analysis
We now use a published cost-effectiveness study to examine the potential consequences of
moving from EQ-5D-3L to EQ-5D-5L as a basis for economic evaluation. We first replicate
the economic evaluation results in Wailoo et al. (2014), which use EQ-5D-3L data collected
as part of a trial. Then we repeat the analysis using EQ-5D-5L obtained using the map-
ping models developed in this paper. Wailoo et al. (2014) estimate the cost-effectiveness of
combinations of disease-modifying anti-rheumatic drugs (DMARDs) and short-term adminis-
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tration of the steroid prednisolone (PNS), using data from the 2-year CARDERA trial which
involved 467 adult patients with early active RA (less than two years of disease duration) in
a placebo-controlled factorial design. Two DMARDS were used in the trial, methotrexate
(MTX) and ciclosporin (CS). All patients received MTX, half received step-down PNS5 and
half CS, generating four treatment groups: (1) monotherapy (MTX only), (2) combination
DMARDs (MTX and CS), (3)DMARD and steroid (MTX and PNS) and (4) triple therapy
(MTX, CS and PNS). Further details of the methods and clinical effectiveness can be found
in Choy et al. (2008).
The key criterion used in cost-effectiveness analysis is the Incremental Cost-Effectiveness
Ratio (ICER), defined as the difference in costs between two different treatment strategies,
expressed as a ratio to the difference in the QALYs that they achieve. Treatments with
ICERs below a certain threshold are usually considered cost-effective. In the UK, NICE
guidance on technology appraisal refers to a specific range £20,000-£30,000 (NICE, 2013),
but see also Claxton et al. (2015) who argue for a lower threshold.
Resource use (prescription drugs, hospitalizations, tests, imaging, surgical procedures
and community care visits) was directly observed over the two years of the trial and costed
using 2011-2012 figures. The mean discounted cost of each treatment strategy is shown in
the first row of Table 7. QALY estimates were derived from EQ-5D-3L responses observed
at baseline and 6, 12, 18 and 24 months. The discounted QALY total was then estimated
as the area under the linear interpolation of the five points. Table 7 presents the mean
costs and QALYs after two years for the sample of patients with complete data (n=241).6
Of all four treatment strategies, triple therapy is the least costly and most effective (higher
QALYs), thus dominating all other strategies. Of the remaining three treatment strategies,
5Initially dosed at 60mg/day, reducing to 7.5mg/day at 6 weeks and stopped by 34 weeks.
6Note that there are minor differences between the numbers reported in Table 7 and those in Wailoo
et al. (2014) due to missing data in the variables used to predict EQ-5D-5L for one patient, but results are
unaffected.
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the DMARD combination is dominated by a DMARD plus steroid, being more costly and less
effective. Monotherapy is more effective but also more costly than MTX plus steroid, with
an ICER of £13,714 which lies comfortably below a conventional cost-effectiveness threshold
of (say) £20,000 per QALY.
We then repeated the estimation of QALYs using EQ-5D-5L predicted from the models
developed in this paper, conditional on the EQ-5D-3L responses observed in the trial. This
was done separately at each 6-monthly observation of EQ-5D-3L and the total computed by
interpolation as before. Note that, since this construction is a linear function of the EQ-5D
responses Y , our use of E(Y5∣Y3,X) as a predictor does not introduce bias into the QALY
evaluation, as it would for a nonlinear function of Y . The independent domains model and
the more complex joint model give very similar results in terms of total QALYs but the
point estimates of the joint model seem to fall below those of the independent domains
model. The mapped EQ-5D-5L QALYs are consistently larger (by 15-25%) than the EQ-
5D-3L QALY estimates, and the six ICERs for pairwise comparisons of the therapies also
increase in magnitude by up to 100%.
These changes are potentially large enough to alter policy decisions. For example, the
ICER comparing monotherapy with combination DMARD+steroid rises from £13,721 to
£21,455 using the independent domains model. If we were to use a cost-effectiveness thresh-
old of £20,000, this would reverse the decision that monotherapy is cost-effective relative
to the DMARD+steroid combination therapy. Using the joint model, the ICER rises to
£18,100, not large enough to reverse the decision but a substantial rise nonetheless.
So there is some support here for the practical use of the independent domains model
(which is implemented in the Stata command bicop) as the predicted QALYs are similar to
the joint model. In this specific case, those small differences still translate into substantial
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differences in the cost-effectiveness estimates because the ICERs are very sensitive to the
incremental QALYs.
Table 7: Mean costs, QALYs and incremental cost-effectiveness ratios for the CARDERA trial
Monotherapy Combination therapies
MTX MTX+CS MTX+PNS MTX+CS+PNS
Total costs1 £7,503 £6,829 £6,323 £6,203
EQ-5D-3L from trial data
Total QALYs 1.238 1.093 1.152 1.320
ICER (for col therapy vs. row therapy)
MTX only - £4,648 £13,714 -£15,929
MTX+CS £4,648 - -£8,597 -£2,765
MTX+PNS £13,714 -£8,597 - -£714
EQ-5D-5L mapped from 3L trial data (independent domains model)
Total QALYs 1.452 1.368 1.397 1.523
ICER (for col therapy vs. row therapy)
MTX only - £8,021 £21,476 -£18,254
MTX+CS £8,021 - -£17,440 -£4,037
MTX+PNS £21,476 -£17,440 - -£952
EQ-5D-5L mapped from 3L trial data (joint model)
Total QALYs 1.440 1.343 1.375 1.504
ICER (for col therapy vs. row therapy)
MTX only - £6,930 £18,100 -£20,141
MTX+CS £6,930 - -£15,819 -£3,873
MTX+PNS £18,100 -£15,819 - -£926
1 Present value of treatment costs over the 2-year experimental period
7 Conclusions
There are three clear conclusions. First, econometric modelling based on a flexible mixture-
copula specification has revealed significant differences between the 3-level and 5-level ver-
sions of the EQ-5D descriptive system for health states. These differences are particularly
striking for the mobility and pain domains, where the two versions of the instrument give
significantly different pictures of the relationship between individual health states and their
demographic and clinical determinants.
28
Second, we have developed a new and powerful technique for modelling and mapping
between the 3-level and 5-level versions of EQ-5D, using an Empirical Bayes conditional
expectation approach. This has revealed some asymmetry. Mapping from EQ-5D-3L ques-
tionnaire responses to predictions of the utility scores for EQ-5D-5L reproduces the directly-
observed distributional shape quite faithfully. In contrast, mapping from the more detailed
EQ-5D-5L responses to predicted utility scores for EQ-5D-3L fails to capture the bunching
of utilities at low or negative values that is characteristics of EQ-5D-3L. This has important
implications for policy bodies like NICE. On the basis of the evidence presented here, NICE
could move to the new 5-level version of EQ-5D as the basis for its decision-making, and use
flexible mapping techniques where necessary to convert old 3-level EQ-5D evidence to the
new basis. It would be unwise to convert newer 5L-based trial evidence back to the old 3L
basis, since mapping does not work well in that context.
Third, our re-examination of evidence from a trial of combination drug therapies for
rheumatoid arthritis shows that switching to the newer 5-level version of EQ-5D can make
a substantial difference to the conclusions from cost-effectiveness studies, so there is likely
to be a need to re-examine past decisions to investigate their robustness. Our new mapping
approach offers a way of doing this and is readily applied using recently-developed computer
code implemented as a Stata command bicop (Herna´ndez-Alava and Pudney, 2016). The
mapping algorithms developed in this paper will also be made freely available as a Stata
command for analysts to use in RA. The threshold historically used for EQ-5D-3L may
require reassessment if the 5-level version of EQ-5D is to be used in future.
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Appendix: full parameter estimates
Table A1 Estimated coefficients of the domain-specific bivariate and joint models
Domain-specific model Joint model
Coefficient Std. error Coefficient Std. error
Mobility domain - 3 levels
male 0.4601 0.0543 0.5125 0.0637
age/10 -0.0117 0.0169 -0.0067 0.0197
pain/10 2.4178 0.3205 2.8928 0.3826
HAQ 1.2370 0.1092 1.3765 0.1347
HAQ2 -0.9591 0.3880 0.0987 0.0627
pain2 0.0593 0.0522 -1.2067 0.4554
HAQ * pain -0.3067 0.1603 -0.3134 0.1907
ψ 0.6494 0.0416
Γ1 1.8996 0.1244 2.2583 0.1547
Γ2 5.6557 0.1634 6.7752 0.2465
Mobility domain - 5 levels
male 0.3390 0.0430 0.3839 0.0504
age/10 0.0506 0.0137 0.0612 0.0159
pain/10 1.9446 0.2525 2.4359 0.2964
HAQ 1.2235 0.0841 1.4009 0.1010
HAQ2 -0.4122 0.3099 0.0610 0.0470
pain2 0.0458 0.0397 -0.6556 0.3606
HAQ * pain -0.3969 0.1283 -0.4656 0.1527
ψ 0.6279 0.0317
Γ1 1.5939 0.0982 1.8964 0.1184
Γ2 2.9367 0.1032 3.4302 0.1321
Γ3 4.2711 0.1093 4.9911 0.1511
Γ4 5.5625 0.1303 6.5589 0.1920
Dependency θ 0.7074 0.0139 0.5956 0.0203
continued...
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Table A1 continued
Domain-specific model Joint model
Coefficient Std. error Coefficient Std. error
Self-care domain - 3 levels
male 0.6103 0.0662 0.6438 0.0688
age/10 -0.1067 0.0204 -0.1096 0.0210
pain/10 1.0591 0.4462 1.4948 0.4722
HAQ 1.8555 0.1966 1.9641 0.2226
HAQ2 -0.6821 0.4457 -0.0444 0.0790
pain2 -0.0314 0.0729 -1.0048 0.4603
HAQ * pain 0.0428 0.2036 0.0040 0.2144
ψ 0.3163 0.0347
Γ1 2.7358 0.1960 2.9350 0.2235
Γ2 5.7598 0.2142 6.1590 0.2565
Self-care domain - 5 levels
male 0.6366 0.0536 0.6779 0.0569
age/10 -0.0949 0.0167 -0.1006 0.0175
pain/10 1.2139 0.3390 1.7335 0.3669
HAQ 1.5870 0.1270 1.7245 0.1432
HAQ2 -0.7787 0.3644 0.0097 0.0561
pain2 0.0182 0.0519 -1.1726 0.3852
HAQ * pain 0.0764 0.1583 0.0276 0.1686
ψ 0.3806 0.0289
Γ1 2.0816 0.1350 2.3131 0.1524
Γ2 3.4855 0.1399 3.7768 0.1627
Γ3 4.9402 0.1512 5.3745 0.1825
Γ4 5.6903 0.1729 6.3115 0.2176
Dependency θ 6.0530 0.3145 5.5022 0.3051
continued...
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Table A1 continued
Domain-specific model Joint model
Coefficient Std. error Coefficient Std. error
Usual activities domain - 3 levels
male 0.2409 0.0539 0.3278 0.0781
age/10 -0.0582 0.0168 -0.0751 0.0240
pain/10 2.6254 0.3175 4.1937 0.4879
HAQ 1.7515 0.1164 2.6488 0.1936
HAQ2 -1.3382 0.3756 -0.3058 0.0709
pain2 -0.1891 0.0503 -2.1676 0.5438
HAQ * pain 0.0196 0.1594 -0.1170 0.2237
ψ 1.0333 0.0819
Γ1 1.7532 0.1278 2.7194 0.2159
Γ2 4.7465 0.1520 6.9414 0.3559
Usual activities domain - 5 levels
male 0.1923 0.0440 0.2462 0.0625
age/10 -0.0751 0.0139 -0.0961 0.0195
pain/10 2.4151 0.2616 3.7146 0.3862
HAQ 1.6059 0.0925 2.2971 0.1437
HAQ2 -1.3418 0.3149 -0.1997 0.0581
pain2 -0.1386 0.0416 -2.0802 0.4497
HAQ * pain 0.0367 0.1325 -0.0395 0.1881
ψ 0.9943 0.0616
Γ1 1.0144 0.0997 1.5766 0.1490
Γ2 2.4708 0.1074 3.6049 0.1854
Γ3 3.9116 0.1188 5.6372 0.2345
Γ4 4.8488 0.1342 6.8882 0.2712
Dependency θ 0.5560 0.0172 0.1019 0.0541
Common mixture
pi 0.0621 0.0461
1 − pi 0.9379 0.0461
µ1 0.2841 0.4314
µ2 -0.0188 0.0217
σ21 3.0482 0.8537
σ22 0.8587 0.0665
continued...
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Table A1 continued
Domain-specific model Joint model
Coefficient Std. error Coefficient Std. error
Pain/discomfort domain - 3 levels
male 0.1737 0.0472 0.2130 0.0562
age/10 0.0332 0.0156 0.0274 0.0181
pain/10 6.3976 0.4445 7.1520 0.4037
HAQ 0.6059 0.0908 0.7806 0.1046
HAQ2 -2.3849 0.4493 -0.1176 0.0551
pain2 -0.1296 0.0488 -3.0418 0.4349
HAQ * pain 0.4015 0.1796 0.1717 0.1849
ψ 0.3705 0.0325
Γ1 0.8379 0.1132 0.9465 0.1241
Γ2 5.1633 0.1728 5.4769 0.1890
pi 0.5871 0.0787
1 − pi 0.4129 0.0787
µ1 -0.0936 0.0528
µ2 0.1331 0.0771
σ21 0.2850 0.0824
σ22 1.9866 0.2359
Pain/discomfort domain - 5 levels
male 0.1085 0.0424 0.1278 0.0484
age/10 -0.0504 0.0137 -0.0605 0.0155
pain/10 6.0189 0.2887 6.9250 0.3362
HAQ 0.6694 0.0819 0.7903 0.0936
HAQ2 -2.6218 0.3451 -0.1119 0.0460
pain2 -0.1042 0.0402 -3.0565 0.3848
HAQ * pain 0.3632 0.1391 0.3352 0.1563
ψ 0.5364 0.0301
Γ1 -0.3351 0.0939 -0.3981 0.1061
Γ2 2.0121 0.1049 2.3200 0.1212
Γ3 4.1984 0.1174 4.7505 0.1437
Γ4 5.3824 0.1280 6.0899 0.1616
pi 0.1075 0.0745
1 − pi 0.8925 0.0745
µ1 0.1204 0.1985
µ2 -0.0145 0.0195
σ21 2.6886 0.7068
σ22 0.7948 0.0830
Dependency θ 1.7094 0.0474 1.5660 0.0452
continued...
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Table A1 continued
Domain-specific model Joint model
Coefficient Std. error Coefficient Std. error
Anxiety/depression domain - 3 levels
male 0.0387 0.0491 0.0469 0.0495
age/10 -0.1350 0.0148 -0.1355 0.0152
pain/10 1.2087 0.2829 1.3453 0.2894
HAQ 0.4322 0.0904 0.4549 0.0923
HAQ2 -0.2623 0.3495 -0.0663 0.0440
pain2 -0.0580 0.0436 -0.4026 0.3550
HAQ * pain 0.1788 0.1471 0.1903 0.1478
ψ 0.3257 0.0259
Γ1 0.4435 0.1033 0.4901 0.1055
Γ2 2.2668 0.1086 2.3920 0.1164
Anxiety/depression domain - 5 levels
male -0.0137 0.0453 -0.0071 0.0462
age/10 -0.1456 0.0137 -0.1482 0.0142
pain/10 1.2094 0.2554 1.3614 0.2640
HAQ 0.3731 0.0826 0.4139 0.0855
HAQ2 -0.4111 0.3179 -0.0526 0.0410
pain2 -0.0387 0.0401 -0.5557 0.3251
HAQ * pain 0.2730 0.1354 0.2818 0.1377
ψ 0.3554 0.0240
Γ1 0.1154 0.0945 0.1625 0.0979
Γ2 1.0888 0.0953 1.1589 0.0999
Γ3 2.0811 0.0998 2.2051 0.1076
Γ4 2.6195 0.1098 2.8087 0.1227
Dependency θ 14.4849 0.5894 13.9413 0.5912
Common mixture - Joint model
pi 0.0250 0.0127
1 − pi 0.9750 0.0127
µ1 -0.5004 0.2528
µ2 0.0128 0.0072
σ21 5.6660 1.6944
σ22 0.8739 0.0286
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